Connective Tissue Growth Factor
A major therapeutic platform at FibroGen is focused on blocking the activity of connective tissue growth factor (CTGF) to treat a variety of diseases.
CTGF Biology
FibroGen is a pioneer in research to understand the biology of connective tissue growth factor (CTGF), a secreted protein that mediates communication between a variety of cell types and their surrounding environment (extracellular matrix). Research implicates CTGF in multiple processes that cause disease including fibrosis, proteinuria, epithelial to mesenchymal transition and reduced cell adhesion. Read more
Anti-CTGF Therapy
FibroGen aims to develop novel anti-CTGF treatments for a variety of diseases in which CTGF-mediated pathologies play a key role. FibroGen’s lead clinical candidate is FG-3019, a fully human monoclonal antibody that targets CTGF, which is expected to provide therapeutic benefit in multiple clinical settings. Read more
Development Programs
FibroGen is actively developing FG-3019 in the following therapeutic target areas:
| Therapeutic Target Area (CTGF-mediated pathologies) | Potential Indications |
|---|---|
| Chronic Kidney Disease (CKD) (proteinuria, epithelial to mesenchymal transition, fibrosis) |
|
| Fibrotic Disease (disruption of extracellular matrix homeostasis) |
|
| Cancer (epithelial to mesenchymal transition, tumor cell growth, angiogenesis, cell adhesion and migration) |
|
